Search

Displaying results 3941 - 3950 of 10000 in total
  1. Drug

    SGN-15

    go.drugbank.com/drugs/DB05818
    Investigational

    SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. … Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic.

  2. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

  3. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

  4. Drug

    Cenisertib

    go.drugbank.com/drugs/DB06347
    Investigational

    Cenisertib is an aurora kinase inhibitor.

  5. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.

  6. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil has received Orphan Drug status from the FDA for the treatment of hepatocellular cancer in combination with fluoropyrimidines (including 5-FU). … GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in

  7. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections.

  8. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  9. Drug

    Golotimod

    go.drugbank.com/drugs/DB05475
    Investigational

    SCV-07 has shown efficacy in treating various viral and bacterial infections. … In independent studies, treatment of tuberculosis with SCV-07 improved clearance of mycobacteria, improved cavity healing, improvements in immune parameters and reduced symptoms (fever, weakness, sweating

  10. Drug

    beta-Hydroxyisovaleric acid

    go.drugbank.com/drugs/DB15344
    Investigational

    beta-Hydroxyisovaleric acid is under investigation in clinical trial NCT03018496 (Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.).